直肠间隔物在前列腺立体定向消融放疗中的疗效:英国首次经验
本研究评估了植入水凝胶直肠间隔物用于前列腺立体定向消融放疗-容积调强弧形治疗(SABR-VMAT)患者的实用性、剂量学影响、正常组织并发症概率(NTCP)和早期毒性。首批6例患者均成功在局麻下置入间隔物,最大毒性为1级;置入后计划直肠剂量指标显著改善,例如直肠接受36 Gy的体积在所有患者中减少≥42%,2级及以上直肠出血的中位NTCP从4.9%显著降至0.8%(p=0.031)。结论认为间隔物使所有患者的直肠剂量在临床和统计学上显著降低。
要点
- 置入间隔物后,所有患者直肠接受36 Gy的体积减少≥42%。
- 2级及以上直肠出血的中位NTCP从4.9%降至0.8%(p=0.031)。
- 所有患者均在局麻下成功置入间隔物,最大毒性为1级。
核心结论
- 间隔物使所有患者的直肠剂量在临床和统计学上显著降低。
研究设计与样本
- 前列腺SABR和直肠间隔物试验中首批6例接受治疗患者的数据分析,比较置入间隔物前CT生成的SABR计划与置入后计划,评估靶区覆盖、适形性和危及器官剂量及NTCP,并收集早期毒性数据。
诊断标准与关键数值
- 置入间隔物后计划中,所有患者直肠接受36 Gy的体积减少≥42%。
- 2级及以上直肠出血的中位NTCP从4.9%显著降至0.8%(p=0.031)。
- 置入间隔物前后计划之间,临床靶区剂量覆盖无显著差异。
局限性
- 本研究为前列腺SABR和直肠间隔物试验中首批6例接受治疗患者的数据分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study assessed the use of implanted hydrogel rectal spacers for stereotactic ablative radiotherapy-volumetric modulated arc therapy (SABR-VMAT) patients, investigating practicality, dosimetric impact, normal tissue complication probability (NTCP) and early toxicity.
METHODS: Data from the first 6 patients treated within a prostate SABR and rectal spacer trial were examined to determine spacer insertion tolerability, resultant changes in treatment planning and dosimetry and early toxicity effects. CT scans acquired prior to spacer insertion were used to generate SABR plans which were compared to post-insertion plans. Plans were evaluated for target coverage, conformity, and organs at risk doses with NTCPs also determined from resultant dose fluences. Early toxicity data were also collected.
RESULTS: All patients had successful spacer insertion under local anaesthetic with maximal Grade 1 toxicity. All plans were highly conformal, with no significant differences in clinical target volume dose coverage between pre- and post-spacer plans. Substantial improvements in rectal dose metrics were observed in post-spacer plans, e.g. rectal volume receiving 36 Gy reduced by ≥42% for all patients. Median NTCP for Grade 2 + rectal bleeding significantly decreased from 4.9 to 0.8% with the use of a rectal spacer (p = 0.031). To date, two episodes of acute Grade 1 proctitis have been reported following treatment.
CONCLUSION: The spacer resulted in clinically and statistically significant reduction in rectal doses for all patients. Advances in knowledge: This is one of the first studies to investigate the efficacy of a hydrogel spacer in prostate SABR treatments. Observed dose sparing of the rectum is predicted to result in meaningful clinical benefit.
引用
- King RB, Osman SO, Fairmichael C, et al. Efficacy of a rectal spacer with prostate SABR-first UK experience. Br J Radiol. 2018. PMID: 29182384. doi:10.1259/bjr.20170672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。